Abstract: This invention relates to primers and probes for detecting Ebola virus and one or more subtypes of Ebola virus as well as kits including the probes and primers and methods of using the probes and primers.
Abstract: The invention is directed to an in vitro method for joining a first set of double-stranded (ds) DNA molecules. Small molecules acting as chaperone agents are identified that promote efficient and rapid assembly (that is, joining) of overlapping double-stranded DNA fragments.
Type:
Grant
Filed:
July 17, 2015
Date of Patent:
April 24, 2018
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Scott D. Rose, Joseph A. Walder, Kristin Beltz, Shawn Allen
Abstract: The invention describes composition and methods of use for novel hairpin blocked-cleavable primers. In one embodiment unblocking occurs through action of RNase H2. The method improves the specificity of PCR and reduces primer dimer events, enabling higher level multiplex reactions. Additionally, the invention protects RNA-containing primers from attack by single-strand RNases.
Type:
Application
Filed:
August 29, 2017
Publication date:
March 1, 2018
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Joseph A. Walder, Joseph Dobosy, Mark Aaron Behlke
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Grant
Filed:
September 8, 2016
Date of Patent:
January 23, 2018
Assignees:
CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
John J Rossi, Mark A. Behlke, Dongho Kim
Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRIPSR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRIPSR Cas9 endonuclease system.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
December 12, 2017
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
Abstract: The invention provides methods for the synthesis of long oligonucleotides, genes and gene fragments. The methods include the manufacture of genes or gene fragments that can be then inserted into a variety of vectors.
Type:
Application
Filed:
May 10, 2017
Publication date:
September 14, 2017
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Shawn Allen, Stephen Gunstream, Scott Rose
Abstract: The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., ribonuclease) substrates, and probes and compositions useful in detection assays.
Type:
Application
Filed:
February 10, 2017
Publication date:
August 10, 2017
Applicants:
UNIVERSITY OF IOWA RESEARCH FOUNDATION, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
James O. McNamara, II, Katie R. Stockdale, Lingyan Huang, Alexander R. Horswill, Mark A. Behlke, Frank J. Hernandez
Abstract: The invention provides a more efficient and less error-prone method of performing LAMP. The invention also provides a method for utilizing an RNase H2-cleavable probe as a technique for generating signal from the reaction, potentially increasing the specificity of the signal generation.
Type:
Application
Filed:
February 1, 2017
Publication date:
August 3, 2017
Applicant:
Integrated DNA Technologies, Inc.
Inventors:
Joseph Dobosy, Aurita Menezes, Caifu Chen, Mark Behlke
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Application
Filed:
December 12, 2016
Publication date:
June 8, 2017
Applicants:
CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
John J. ROSSI, Mark A. BEHLKE, Dongho KIM
Abstract: The invention provides methods for the synthesis of long oligonucleotides, genes and gene fragments. The methods include the manufacture of genes or gene fragments that can be then inserted into a variety of vectors.
Type:
Grant
Filed:
September 25, 2015
Date of Patent:
June 6, 2017
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Shawn Allen, Stephen Gunstream, Scott Rose
Abstract: The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3? end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein.
Type:
Grant
Filed:
August 5, 2013
Date of Patent:
May 9, 2017
Assignee:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Joseph Alan Walder, Mark Aaron Behlke, Scott Rose, Joesph Dobosy
Abstract: The present invention relates to a rapid detection of microbial-associated nuclease activity with chemically modified nuclease (e.g., ribonuclease) substrates, and probes and compositions useful in detection assays. Accordingly, in certain embodiments, the present invention provides a probe for detecting a microbial endonuclease comprising a substrate oligonucleotide of 2-30 nucleotides in length, a fluorescence-reporter group operably linked to the oligonucleotide, and a fluorescence-quencher group operably linked to the oligonucleotide. The fluorescence-reporter group and the fluorescence-quencher group are separated by at least one RNAse-cleavable residue, e.g., RNA base.
Type:
Grant
Filed:
August 30, 2012
Date of Patent:
March 28, 2017
Assignees:
University of Iowa Research Foundation, Integrated DNA Technologies, Inc.
Inventors:
James O. McNamara, II, Katie R. Stockdale, Lingyan Huang, Alexander R. Horswill, Mark A. Behlke, Frank J. Hernandez
Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.
Type:
Application
Filed:
October 21, 2016
Publication date:
February 16, 2017
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.
Type:
Application
Filed:
October 21, 2016
Publication date:
February 16, 2017
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
Abstract: This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system.
Type:
Application
Filed:
October 21, 2016
Publication date:
February 16, 2017
Applicant:
INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
Michael Allen Collingwood, Ashley Mae Jacobi, Garrett Richard Rettig, Mollie Sue Schubert, Mark Aaron Behlke
Abstract: This invention pertains to improved methods for the synthesis of long, double stranded nucleic acid sequences containing difficult to clone or variable regions.
Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
Type:
Grant
Filed:
January 9, 2013
Date of Patent:
January 10, 2017
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.
Type:
Application
Filed:
September 8, 2016
Publication date:
December 29, 2016
Applicants:
CITY OF HOPE, INTEGRATED DNA TECHNOLOGIES, INC.
Inventors:
John J. ROSSI, Mark A. Behlke, Dongho Kim
Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
Type:
Grant
Filed:
September 26, 2014
Date of Patent:
November 29, 2016
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Mark Aaron Behlke, Richard Owczarzy, Yong You, Joseph Alan Walder, Kim Lennox
Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.
Type:
Grant
Filed:
February 25, 2013
Date of Patent:
November 29, 2016
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Mark Aaron Behlke, Kimberly Ann Lennox, Ashley Mae Jacobi, Richard Owczarzy, Joseph Alan Walder